GeneDx Holdings Corp. WGS
54.83 USD -10.89 (-16.57%)
At closeNov 11, 2026, 4:39 AM EST
54.99 +0.16 +0.29%
Pre-market · Nov 11, 4:39 AM ET
52.89 Day range 58.07
32.21 52-week range 170.87
- YTD
- -57.84%
- 1 year
- -60.81%
- Market cap
- 1.64B
- Revenue (ttm)
- 460.78M
- Profit margin
- -24.10%
- EPS (ttm)
- -3.76
- Shares out
- 29.82M
- Forward P/E
- 53.62
- YTD return
- -57.84%
- 1-year return
- -60.81%
- Volume
- 3.36M
- Avg volume
- 740.03K
- Open
- 56.11
- Previous close
- 65.72
- Day's range
- 52.89 – 58.07
- 52-week range
- 32.21 – 170.87
- Analysts
- Strong Buy
- Price target
- 91.00 (+66.0%)
- Earnings date
- Feb 22, 2027
5D -15.01 (-21.49%)
Key statistics
- Enterprise value
- 2.02B
- PEG ratio
- 0.00
- Price / sales
- 3.55
- Price / book
- 6.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 5.40%
- Free cash flow
- -73.90M
- Total cash
- 170.12M
- Total debt
- 215.38M
- Return on equity
- -41.36%
- Short % of float
- 38.65%
- 50-day average
- 76.42
- 200-day average
- 70.80
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 91.00 +66.0% upside
Now 54.83
- Target (low)
- 80.00
- Target (mean)
- 91.00
- Target (high)
- 103.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy1
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 22, 2027
Expected Feb 22, 2027. Consensus EPS estimate 0.2975.
Financials — quick view
WGS Revenue — quarterly 123.10M
WGS Net income — quarterly -12.33M
WGS EPS — quarterly -0.41
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 22, 2027 | Dec 30, 2026 | 0.31 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | 0.07286 | 0.28 | +0.21 | +284.30% |
| Aug 3, 2026 | Jun 30, 2026 | -0.18787 | 0.01 | +0.20 | +105.32% |
| May 4, 2026 | Mar 31, 2026 | -0.06 | -0.28 | -0.22 | -366.67% |
| Feb 23, 2026 | Dec 31, 2025 | 0.11 | 0.14 | +0.03 | +27.27% |
| Oct 28, 2025 | Sep 30, 2025 | 0.28 | 0.49 | +0.21 | +75.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | BTIG | main | Buy | Buy |
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
| Aug 4, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 4, 2026 | BTIG | reit | Buy | Buy |
| Jun 29, 2026 | Guggenheim | main | Buy | Buy |
| Jun 23, 2026 | Piper Sandler | main | Overweight | Overweight |
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- genedx.com
News
Why GeneDx Holdings Stock Just Dropped 16.6% 
GeneDx To Present New Research At The National Society Of Genetic Counselors Conference, November 11-14; Data Show 62% Of Patients With Pathogenic Or Likely Pathogenic Findings Had Results Associated With Opportunities To Inform Medical Management 
Groupon Posts Downbeat Q3 Results, Joins GeneDx Holdings, Qualys And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Why Sanmina Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket 
BTIG Maintains Buy on GeneDx Holdings, Lowers Price Target to $85 
GeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call Transcript 
GeneDx: Q3 Earnings Indicate Transition To Sustained Profitability 
GeneDx Q3 Earnings Call Highlights 
GeneDx Holdings Q3 2026 Earnings Call Transcript
Your note
Sign in to keep a note on WGS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CASDIN CAPITAL, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 4, 2026 | 0 |
| CASDIN ELI | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 17, 2026 | 4,083,650 |
| FEELEY KEVIN | Chief Financial Officer | Sale | Sep 8, 2026 | 41,476 |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 17, 2024 | 2,719,690 |
| LEPROUST EMILY M | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 24,852 |
| MEISTER KEITH A | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 17, 2026 | 5,141,420 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Corvex Management LP | 16.04% | 4,784,570 | 262.34M | Jun 29, 2026 |
| Casdin Capital, LLC | 12.43% | 3,707,164 | 203.26M | Jun 29, 2026 |
| Blackrock Inc. | 5.72% | 1,706,239 | 93.55M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 5.60% | 1,669,441 | 91.54M | Jun 29, 2026 |
| ARK Investment Management, LLC | 5.40% | 1,610,189 | 88.29M | Jun 29, 2026 |
| William Blair Investment Management, LLC | 5.23% | 1,560,247 | 85.55M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 3.74% | 1,116,678 | 61.23M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.04% | 607,773 | 33.32M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.74% | 518,235 | 28.41M | Sep 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.73% | 515,373 | 28.26M | Sep 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 0.89% | 266,042 | 14.59M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.84% | 249,890 | 13.70M | Jun 29, 2026 |